Joseph Bordelon, MD
Sleep Medicine · Opelousas, LANPI 1972685279
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 436 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,738 and has fallen 97.7% since, to $40 in 2025.
Across 436 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Mylan Specialty L.p.$812
- Jazz Pharmaceuticals Inc.$690
- Regeneron Healthcare Solutions, Inc.$488
- Sunovion Pharmaceuticals Inc.$479
- plus $2K from 28 others
What the payments were for
- Food & beverage$7,754100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 113 | $1,775 |
| AstraZeneca | 62 | $1,045 |
| Mylan Specialty L.p. | 37 | $812 |
| Jazz Pharmaceuticals Inc. | 34 | $690 |
| Regeneron Healthcare Solutions, Inc. | 23 | $488 |
| Sunovion Pharmaceuticals Inc. | 39 | $479 |
| Novartis | 17 | $298 |
| Sanofi | 8 | $237 |
| Harmony Biosciences LLC | 12 | $228 |
| Baxter Healthcare | 11 | $220 |
| Boehringer Ingelheim | 14 | $211 |
| Actelion Pharmaceuticals US, Inc. | 12 | $205 |
| Bayer | 11 | $171 |
| Eisai Inc. | 1 | $125 |
| Amgen | 6 | $95 |
| Mayne Pharma Commercial LLC | 4 | $86 |
| Axsome Therapeutics, Inc. | 3 | $79 |
| Grifols USA, LLC | 4 | $71 |
| Arbor Pharmaceuticals, Inc. | 4 | $60 |
| Pfizer | 4 | $56 |
| Getinge USA Sales, LLC | 2 | $45 |
| Medtronic | 1 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Ambu Inc. | 1 | $25 |
| Insmed, Inc. | 2 | $25 |
| Johnson & Johnson | 1 | $24 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Exact Sciences | 1 | $17 |
| Phadia US Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Inogen, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$122
How this compares
$7,754 in reported general payments places this provider in the 80th percentile of 20 sleep medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 24 | $467,889 |
| WakixPitolisant Hcl | 11 | $87,412 |
| NuplazidPimavanserin Tartrate | 11 | $64,211 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $18,045 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,777 |
| BelsomraSuvorexant | 16 | $6,868 |
| Modafinil | 29 | $1,345 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 37 | $980 |
| SynthroidLevothyroxine Sodium | 14 | $649 |
| Pregabalin | 14 | $387 |
| Doxepin Hcl | 24 | $370 |
| Carisoprodol | 12 | $345 |
| Promethazine Hcl | 15 | $331 |
| Temazepam | 33 | $299 |
| Zolpidem Tartrate | 47 | $289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $228 | $87,41211 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,775 | $25,82140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 20 sleep medicine providers in Louisiana.
Other sleep medicine in Opelousas
- Matthew AbrahamLafayette$23K
- Sara MunjampalliShreveport$19K
- Oleg ChernyshevShreveport$15K
- Dwayne HenryBaton Rouge$6K
- Brittany MonceauxShreveport$4K
- Lauren DavisCovington$4K
- Liudmila LysenkoNew Orleans$3K
- Clinton YoungLafayette$3K
- Naomi GhildiyalShreveport$3K
- Abigail BoudreauxNew Orleans$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.